Veneto Tumour Registry, Azienda Zero, Padova, Italy.
Endoscopy Unit, Nuovo Regina Margherita, Roma, Italy.
J Med Screen. 2021 Jun;28(2):131-139. doi: 10.1177/0969141320918613. Epub 2020 May 11.
To assess faecal immunochemical test sensitivity for cancer in a very large population-based cohort followed up for six rounds with biennial faecal immunochemical test repetition.
This study is based on interval colorectal cancers diagnosed in a cohort of subjects aged 50-69 undergoing repeated faecal immunochemical test screening (six rounds) from 2002 to 2015. Test sensitivity was calculated using both the Proportional Interval Cancer Rate and the Interval Cancer Proportion method.
Among 441,647 faecal immunochemical tests (123,347 individuals), 150 interval colorectal cancers were detected after a negative faecal immunochemical test. Interval colorectal cancer incidence rate was 1.87 per 10,000 person-years (95%CI: 1.60-2.20), and it was higher during the second interval year (rate ratio: 1.78; 95%CI: 1.28-2.47), for proximal locations (rate ratio: 3.00; 95%CI: 1.92-4.68), and among 60-71 year old subjects (rate ratio: 2.37; 95%CI: 1.61-3.50). The Proportional Interval Cancer Rate was 13.1%, with an overall faecal immunochemical test sensitivity of 86.9% (95%CI: 84.7-89.0). Sensitivity was lowest at the first round (81.5%; 95%CI: 75.6-86.2), and increased to 91.9% (95%CI: 83.9-96.5) for subsequent rounds. Applying the Interval Cancer Proportion method, sensitivity was 83.9% (95%CI: 81.3-86.2), and it was highest at the first round (89.0%; 95%CI: 85.7-91.6), ranging between 73% and 83.1% at subsequent rounds.
A faecal immunochemical test sensitivity for cancer higher than 80% resulted in a low incidence of interval colorectal cancers, representing an accurate estimate of one of the major limits of screening programmes. Due to intrinsic biases, the Proportional Interval Cancer Rate and the Interval Cancer Proportion methods generated different trends in faecal immunochemical test sensitivity by screening round.
在一项随访 6 轮、每两轮重复进行粪便免疫化学检测的大型基于人群队列中,评估粪便免疫化学检测对癌症的敏感性。
本研究基于 2002 年至 2015 年期间接受重复粪便免疫化学检测筛查(6 轮)的 50-69 岁人群队列中诊断的间隔期结直肠癌病例。使用比例间隔癌症发生率和间隔癌症比例法计算检测敏感性。
在 441647 次粪便免疫化学检测(123347 人)中,150 例间隔期结直肠癌在粪便免疫化学检测阴性后被检出。间隔期结直肠癌发生率为 1.87/10000 人年(95%CI:1.60-2.20),且在第 2 个间隔年内更高(率比:1.78;95%CI:1.28-2.47),在近端位置(率比:3.00;95%CI:1.92-4.68)和 60-71 岁的人群中(率比:2.37;95%CI:1.61-3.50)更高。比例间隔癌症发生率为 13.1%,粪便免疫化学检测总体敏感性为 86.9%(95%CI:84.7-89.0)。第一轮的敏感性最低(81.5%;95%CI:75.6-86.2),随后各轮次敏感性增加至 91.9%(95%CI:83.9-96.5)。应用间隔癌症比例法,敏感性为 83.9%(95%CI:81.3-86.2),在第一轮时最高(89.0%;95%CI:85.7-91.6),随后各轮次介于 73%至 83.1%之间。
粪便免疫化学检测对癌症的敏感性高于 80%,导致间隔期结直肠癌的发生率较低,这代表了筛查计划的一个主要局限性的准确估计。由于内在偏倚,比例间隔癌症发生率和间隔癌症比例法在筛查轮次中产生了不同的粪便免疫化学检测敏感性趋势。